Startup Scouting for Corporations
|
See Aviceda's full profile BOOK A DEMO |
| Headquarters United States |
Founded Year 2019 |
Total Funding
$4.3M |
Employees
1 - 10 |
Status Active |
About AvicedaOur GCT nanoparticles are designed for optimal therapeutic durability and maximum therapeutic efficacy while utilizing the most effective route of administration. |
HeadquartersUnited States |
General Information on Aviceda
| Brand name | Aviceda |
| Company name | AVICEDA THERAPEUTICS Inc. |
| Website | https://www.avicedarx.com/ |
| Founded year | 2019 |
| Employees | 1 - 10 |
| Contact | +16173320741 |
|
Find startup solutions in your specific business context The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
|
BOOK A DEMO |
Recent News and Activity about Aviceda |
|
Ophthalmology Times
•
08.12.2022
Aviceda announces completion of key IND toxicity milestone with positive safety profile in non-human primatesAviceda Therapeutics this week announced the completion of IND-enabling Good Laboratory Practice (GLP) toxicity studies in two species (total of 80 animals) as agreed upon in discussions with the FDA. According to a news release, Aviceda noted that it has shown positive safety data for multiple well-tolerated doses of its lead drug candidate (known as AVD-104, a novel glycan-coated nanoparticle) from dose-range finding studies in non-human ... |
|
PharmiWeb.com
•
05.12.2022
Aviceda Announces Successful Completion of Key IND Toxicity Milestone with Favorable Safety Profile in Non-Human PrimatesAviceda Therapeutics has completed a key IND-enabling milestone for its HALOS™ ( H igh- A ffinity L igands o f S igelcs ) technology platform by demonstrating a very favorable safety profile at numerous tolerated doses of its lead ophthalmic drug candidate, AVD-104, in non-human primates and rabbits. The results represent a major step towards first in-human clinical studies for this program - the first potential therapy for patients with ... 
|
|
FOX 40 WICZ TV
•
25.07.2022
Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development OfficerTarek Hassan, MD: Past President of American Society of Retina Specialists and Retina World Congress; Clinical researcher: global randomized clinical trials (>150), peer-reviewed (230); founder 6 medical device and/or medical education companies; holder of numerous issued patents and inventions CAMBRIDGE, Mass. --(BUSINESS WIRE) Aviceda Therapeutics, Inc. a private biotechnology company located in Cambridge MA with a proprietary ... 
|
|
Jotup
•
27.09.2021
Aviceda Therapeutics Announces Strategic Alliance with University of GeorgiaContent Key Points: CCRC at university of Georgia has an impressive track record of cutting-edge research in glycochemistry and glycobiology, as well as in innate immunity. We are excited to collaborate with CCRC in our efforts and look forward to build next generation glyco-therapeutics together. The expertise and infrastructure at CCRC will be invaluable to the rapid progression of glyco-therapeutics into clinical studies, he added. Under this ... |
|
Jotup
•
20.09.2021
Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Boardpower of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts. Content Key Points: Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune ... |
|
The Galveston County Daily News
•
20.09.2021
Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board Sep 20, 2021 32 min agothe next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts. The new additional Aviceda Scientific Advisory Board members includes: Yvette van Kooyk, PhD Richard Kennedy, MD, PhD Jim Johnston, PhD “Aviceda is honored and ... 
|
|
The Bakersfield
•
20.09.2021
Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board Coronavirus Cases widgetThe new additional Aviceda Scientific Advisory Board members includes:Yvette van Kooyk, PhDRichard Kennedy, MD, PhDJim Johnston, PhD“Aviceda is honored and privileged to add new world-class scientists and renowned researchers to join our efforts in developing the next generation of glyco-immune therapeutics for the treatment of immune-dysfunction conditions,” said Mohamed A. Genead, MD, Co-Founder & President of Aviceda Therapeutics.Prof. Van ... |
|
azcentral.com (Arizona)
•
20.09.2021
Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board | Help Center - The Arizona RepublicAviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the |
Footer
About INNOSPOT
